

Special Issue

Neurocognitive Disorder: Diagnostic Methods, Treatment Challenges and Future Directions

Message from the Guest Editor

Alzheimer's disease (AD) is a neurodegenerative disease with a rising incidence among elderly people. It was first described in 1906 by a clinical psychiatrist and neuroanatomist named Alois Alzheimer. AD is the most common form of dementia and is characterized by progressive memory impairment. The worldwide prevalence of persons with dementia was 35.5 million in 2010, with the number of patients with dementia almost doubling every 20 years, being expected to reach 65.7 million in 2030 and 115.4 million in 2050. The early identification and treatment of patients with dementia should therefore be a public health priority. In the DSM-5, the terms mild cognitive impairment and dementia were replaced by the terms mild neurocognitive disorder (NCD) and major NCD. In this Special Issue, we welcome contributions in the form of original research, review articles on the study of diagnostic and prognostic biomarkers of NCD (neurophysiological, genetic and neuroimaging), as well as articles examining novel methods and future directions for NCD progression, diagnosis and treatment.

Guest Editor

Dr. Vasileios Papaliagkas

Department of Biomedical Sciences, Alexander Campus, International Hellenic University, P.O. Box 141, Sindos, 57400 Thessaloniki, Greece

Deadline for manuscript submissions

closed (31 August 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/184005

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).